February 11, 2013 - Holaira, a medical device manufacturer based in Minneapolis, Minnesota, announced that it was able to successfully raise $10 million from investors in its latest financing round. According to a press release from the company, funds from the latest round will be used to pursue commercialization of its lung denervation system. The company’s lung denervation system is used for the treatment of chronic obstructive pulmonary disease (COPD).
In its press release, the company provided further detail about the Series C financing round. All of the company’s existing backers participated in the latest round. This includes investment groups and venture capitalists like Versant Ventures, Split Rock Partners, Morgenthaler Ventures and Advanced Technology Ventures.
Dr. Dennis Wahr is the CEO of Holaira. In prepared remarks, he said, "The completion of this financing signals continued confidence in the direction of our program to develop a system to enable a minimally invasive bronchoscopic treatment for COPD."
- Learn how GW Plastics Perfected the Design and Production of a Tissue Marker Device - Supplier Resource
- Learn Why Leading Healthcare Companies Rely on GW Plastics for Innovative Solutions, from Concept to Market - Supplier Resource
- Learn how GW Plastics Re-Designed, Re-Engineered and Re-Tooled an Intricate Breast Biopsy Device - Supplier Resource
- Meeting Unique Device Identification (UDI) Requirements with Laser Marking - Supplier Resource
- Wireless Medical Devices Conference - Event
- BIOMEDevice San Jose - Event